// App-Quantinova.ai

e20596 : Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis.

Researchers

Presenter

  • Kaname Nosaki

Principal Investigators

  • Yoshimasa Shiraishi

  • Fumihiko Hirai

  • Taishi Harada

  • Daisuke Himeji

  • Takeshi Kitazaki

  • Noriyuki Ebi

  • Akinobu Hamada

  • Takeharu Yamanaka

  • Mitsuhiro Takenoyama

  • Kenji Sugio

Medical Centers

  • Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  • Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

  • Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan

  • Department of Respiratory Disease, Japan Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan

  • Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan

  • Division of Clinical Pharmacology & Translational Research, National Cancer Center Hospital, Tokyo, Japan

  • Department of Biostatistics Yokohama City University School of Medicine, Yokohama, Japan

  • Department of Thoracic and Breast Surgery, Oita University, Oita, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Leptomeningeal Metastasis

  • Small cell lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Cerebrospinal fluid

Drug/Treatment

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved